

SAFETY DATA SHEET



Ganirelix Formulation



Version 3.4 Revision Date: 04/09/2021 SDS Number: 22196-00017 Date of last issue: 10/16/2020
Date of first issue: 10/15/2014

SECTION 1. IDENTIFICATION

Product name : Ganirelix Formulation
Other means of identification : No data available

Manufacturer or supplier's details

Company name of supplier : Organon & Co.
Address : 30 Hudson Street, 33nd floor
Jersey City, New Jersey, U.S.A 07302
Telephone : 551-430-6000
Emergency telephone : 215-631-6999
E-mail address : EHSSTEWARD@organon.com

Recommended use of the chemical and restrictions on use


Recommended use : Pharmaceutical
Restrictions on use : Not applicable

SECTION 2. HAZARDS IDENTIFICATION

GHS classification in accordance with the Hazardous Products Regulations

Reproductive toxicity : Category 1B
Specific target organ toxicity : Category 1 (Bone marrow, Liver, Adrenal gland, spleen, Ovary)
- repeated exposure

GHS label elements

Hazard pictograms : 

Signal Word : Danger

Hazard Statements : H360Fd May damage fertility. Suspected of damaging the unborn child.
H372 Causes damage to organs (Bone marrow, Liver, Adrenal gland, spleen, Ovary) through prolonged or repeated exposure.

Precautionary Statements : **Prevention:**
P201 Obtain special instructions before use.
P202 Do not handle until all safety precautions have been read and understood.
P260 Do not breathe mist or vapors.
P264 Wash skin thoroughly after handling.
P270 Do not eat, drink or smoke when using this product.
P280 Wear protective gloves, protective clothing, eye protection and face protection.

Response:
P308 + P313 IF exposed or concerned: Get medical attention.

SAFETY DATA SHEET



Ganirelix Formulation



Version 3.4 Revision Date: 04/09/2021 SDS Number: 22196-00017 Date of last issue: 10/16/2020
Date of first issue: 10/15/2014

Storage:

P405 Store locked up.

Disposal:

P501 Dispose of contents and container to an approved waste disposal plant.

Other hazards

None known.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	Common Name/Synonym	CAS-No.	Concentration (% w/w)
Ganirelix	No data available	124904-93-4	$\geq 0.01 - < 0.1$ *

* Actual concentration or concentration range is withheld as a trade secret

SECTION 4. FIRST AID MEASURES

- General advice : In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice.
- If inhaled : If inhaled, remove to fresh air.
Get medical attention.
- In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water.
Remove contaminated clothing and shoes.
Get medical attention.
Wash clothing before reuse.
Thoroughly clean shoes before reuse.
- In case of eye contact : Flush eyes with water as a precaution.
Get medical attention if irritation develops and persists.
- If swallowed : If swallowed, DO NOT induce vomiting.
Get medical attention.
Rinse mouth thoroughly with water.
- Most important symptoms and effects, both acute and delayed : May damage fertility. Suspected of damaging the unborn child.
Causes damage to organs through prolonged or repeated exposure.
- Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
- Notes to physician : Treat symptomatically and supportively.

SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media : Water spray

SAFETY DATA SHEET



Ganirelix Formulation



Version 3.4 Revision Date: 04/09/2021 SDS Number: 22196-00017 Date of last issue: 10/16/2020
Date of first issue: 10/15/2014

- Alcohol-resistant foam
Carbon dioxide (CO₂)
Dry chemical
- Unsuitable extinguishing media : None known.
- Specific hazards during fire fighting : Exposure to combustion products may be a hazard to health.
- Hazardous combustion products : No hazardous combustion products are known
- Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.
- Special protective equipment for fire-fighters : In the event of fire, wear self-contained breathing apparatus.
Use personal protective equipment.
-

SECTION 6. ACCIDENTAL RELEASE MEASURES

- Personal precautions, protective equipment and emergency procedures : Use personal protective equipment.
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).
- Environmental precautions : Avoid release to the environment.
Prevent further leakage or spillage if safe to do so.
Prevent spreading over a wide area (e.g., by containment or oil barriers).
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.
- Methods and materials for containment and cleaning up : Soak up with inert absorbent material.
For large spills, provide diking or other appropriate containment to keep material from spreading. If diked material can be pumped, store recovered material in appropriate container.
Clean up remaining materials from spill with suitable absorbent.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.
-

SECTION 7. HANDLING AND STORAGE

- Technical measures : See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.
- Local/Total ventilation : If sufficient ventilation is unavailable, use with local exhaust ventilation.
- Advice on safe handling : Do not get on skin or clothing.
-

Ganirelix Formulation

Version 3.4 Revision Date: 04/09/2021 SDS Number: 22196-00017 Date of last issue: 10/16/2020
 Date of first issue: 10/15/2014

- Do not breathe mist or vapors.
 Do not swallow.
 Avoid contact with eyes.
 Wash skin thoroughly after handling.
 Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment
 Keep container tightly closed.
 Do not eat, drink or smoke when using this product.
 Take care to prevent spills, waste and minimize release to the environment.
- Conditions for safe storage : Keep in properly labeled containers.
 Store locked up.
 Keep tightly closed.
- Materials to avoid : Do not store with the following product types:
 Strong oxidizing agents
 Organic peroxides
 Explosives
 Gases

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Ganirelix	124904-93-4	TWA	0.2 µg/m ³ (OEB 5)	Internal
		Wipe limit	2 µg/100 cm ²	Internal

- Engineering measures** : Use closed processing systems or containment technologies to control at source (e.g., glove boxes/isolators) and to prevent leakage of compounds into the workplace.
 All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.
 No open handling permitted.
 Totally enclosed processes and materials transport systems are required.
 Operations require the use of appropriate containment technology designed to prevent leakage of compounds into the workplace.

Personal protective equipment

- Respiratory protection : No personal respiratory protective equipment normally required.
- Hand protection
- Material : Chemical-resistant gloves
- Remarks : Consider double gloving.
- Eye protection : Wear safety glasses with side shields or goggles.

SAFETY DATA SHEET



Ganirelix Formulation



Version	Revision Date:	SDS Number:	Date of last issue: 10/16/2020
3.4	04/09/2021	22196-00017	Date of first issue: 10/15/2014

Skin and body protection	: : Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.
Hygiene measures	: If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use. The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance	: Aqueous solution
Color	: No data available
Odor	: No data available
Odor Threshold	: No data available
pH	: 5
Melting point/freezing point	: No data available
Initial boiling point and boiling range	: 100 °C
Flash point	: No data available
Evaporation rate	: No data available
Flammability (solid, gas)	: Not applicable
Flammability (liquids)	: No data available
Upper explosion limit / Upper flammability limit	: No data available
Lower explosion limit / Lower flammability limit	: No data available
Vapor pressure	: 23 hPa (20 °C)

SAFETY DATA SHEET



Ganirelix Formulation



Version 3.4 Revision Date: 04/09/2021 SDS Number: 22196-00017 Date of last issue: 10/16/2020
Date of first issue: 10/15/2014

Relative vapor density : No data available

Relative density : 1

Solubility(ies)
Water solubility : completely miscible

Partition coefficient: n-octanol/water : No data available

Autoignition temperature : No data available

Decomposition temperature : No data available

Viscosity
Viscosity, kinematic : No data available

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Molecular weight : No data available

Particle size : No data available

SECTION 10. STABILITY AND REACTIVITY

Reactivity : Not classified as a reactivity hazard.

Chemical stability : Stable under normal conditions.

Possibility of hazardous reactions : Can react with strong oxidizing agents.

Conditions to avoid : None known.

Incompatible materials : Oxidizing agents

Hazardous decomposition products : No hazardous decomposition products are known.

SECTION 11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure

Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity

Not classified based on available information.

Components:

Ganirelix:

Acute toxicity (other routes of administration) : LD50 (Rat): 40 mg/kg

Skin corrosion/irritation

Not classified based on available information.

Ganirelix Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10/16/2020
3.4	04/09/2021	22196-00017	Date of first issue: 10/15/2014

Serious eye damage/eye irritation

Not classified based on available information.

Components:**Ganirelix:**

Species	:	Rabbit
Result	:	Mild eye irritation
Method	:	Draize Test

Respiratory or skin sensitization**Skin sensitization**

Not classified based on available information.

Respiratory sensitization

Not classified based on available information.

Components:**Ganirelix:**

Test Type	:	Maximization Test
Species	:	Guinea pig
Result	:	negative

Germ cell mutagenicity

Not classified based on available information.

Components:**Ganirelix:**

Genotoxicity in vitro	:	Test Type: reverse mutation assay
		Test system: Salmonella typhimurium
		Result: negative
		Test Type: reverse mutation assay
		Test system: Escherichia coli
		Result: negative
		Test Type: in vitro test
		Test system: Chinese hamster ovary cells
		Result: negative
Genotoxicity in vivo	:	Test Type: In vivo micronucleus test
		Species: Mouse
		Application Route: Intravenous
		Result: negative
Germ cell mutagenicity - Assessment	:	Weight of evidence does not support classification as a germ cell mutagen.

Carcinogenicity

Not classified based on available information.

Ganirelix Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10/16/2020
3.4	04/09/2021	22196-00017	Date of first issue: 10/15/2014

Reproductive toxicity

May damage fertility. Suspected of damaging the unborn child.

Components:**Ganirelix:**

- Effects on fertility : Test Type: Fertility/early embryonic development
Species: Rat
Application Route: Subcutaneous
Duration of Single Treatment: 13 Weeks
Fertility: LOAEL: 0.1 µg/kg
Result: Effects on fertility.
- Test Type: Fertility/early embryonic development
Species: Rat, female
Application Route: Subcutaneous
Duration of Single Treatment: 8 Weeks
Fertility: LOAEL: 10 µg/kg
Result: No effects on mating performance., Effects on fertility.
- Test Type: Fertility
Species: Monkey
Application Route: Subcutaneous
Fertility: NOAEL: 0.02 mg/kg body weight
Result: Effects on fertility.
- Effects on fetal development : Test Type: Embryo-fetal development
Species: Rat, female
Application Route: Subcutaneous
Embryo-fetal toxicity.: LOAEL: 10 µg/kg
Result: Embryo-fetal toxicity.
- Test Type: Embryo-fetal development
Species: Rabbit, female
Application Route: Subcutaneous
Embryo-fetal toxicity.: LOAEL: 30 µg/kg
Result: Embryo-fetal toxicity.
- Reproductive toxicity - Assessment : Clear evidence of adverse effects on sexual function and fertility, based on animal experiments., Some evidence of adverse effects on development, based on animal experiments.

STOT-single exposure

Not classified based on available information.

STOT-repeated exposure

Causes damage to organs (Bone marrow, Liver, Adrenal gland, spleen, Ovary) through prolonged or repeated exposure.

Components:**Ganirelix:**

- Routes of exposure : Ingestion
Target Organs : Bone marrow, Liver, Adrenal gland, spleen, Ovary

SAFETY DATA SHEET



Ganirelix Formulation



Version 3.4 Revision Date: 04/09/2021 SDS Number: 22196-00017 Date of last issue: 10/16/2020
Date of first issue: 10/15/2014

Assessment : Causes damage to organs through prolonged or repeated exposure.

Repeated dose toxicity

Components:

Ganirelix:

Species : Rat
NOAEL : 0.02 mg/kg
LOAEL : 2 mg/kg
Application Route : Subcutaneous
Exposure time : 6 Months
Target Organs : Bone marrow

Species : Mouse, female
LOAEL : 0.3 mg/kg
Application Route : Subcutaneous
Exposure time : 3 Months
Target Organs : Liver, Adrenal gland, spleen, Ovary

Species : Mouse, male
LOAEL : 3 mg/kg
Application Route : Subcutaneous
Exposure time : 3 Months
Target Organs : Liver, Adrenal gland, spleen

Species : Monkey
NOAEL : 2.5 mg/kg
Application Route : Subcutaneous
Exposure time : 6 Months
Remarks : No significant adverse effects were reported

Aspiration toxicity

Not classified based on available information.

Experience with human exposure

Components:

Ganirelix:

Inhalation : Symptoms: The most common side effects are:, vaginal bleeding, Headache, Abdominal pain, Nausea, ectopic pregnancy, miscarriage

SECTION 12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

Ganirelix:

Ecotoxicology Assessment

Acute aquatic toxicity : No data available

SAFETY DATA SHEET



Ganirelix Formulation



Version Revision Date: SDS Number: Date of last issue: 10/16/2020
3.4 04/09/2021 22196-00017 Date of first issue: 10/15/2014

Chronic aquatic toxicity : No data available

Persistence and degradability

No data available

Bioaccumulative potential

No data available

Mobility in soil

No data available

Other adverse effects

No data available

SECTION 13. DISPOSAL CONSIDERATIONS

Disposal methods

Waste from residues : Dispose of in accordance with local regulations.
Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION

International Regulations

UNRTDG

Not regulated as a dangerous good

IATA-DGR

Not regulated as a dangerous good

IMDG-Code

Not regulated as a dangerous good

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

Domestic regulation

TDG

Not regulated as a dangerous good

SECTION 15. REGULATORY INFORMATION

The ingredients of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

SAFETY DATA SHEET



Ganirelix Formulation



Version	Revision Date:	SDS Number:	Date of last issue: 10/16/2020
3.4	04/09/2021	22196-00017	Date of first issue: 10/15/2014

SECTION 16. OTHER INFORMATION

Full text of other abbreviations

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECl - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

Sources of key data used to compile the Material Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Revision Date : 04/09/2021
Date format : mm/dd/yyyy

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

SAFETY DATA SHEET



Ganirelix Formulation



Version	Revision Date:	SDS Number:	Date of last issue: 10/16/2020
3.4	04/09/2021	22196-00017	Date of first issue: 10/15/2014

CA / Z8